In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

Conditions are getting a bit more challenging for the drugmaker.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

Year-over-year BioSpace data shows there are fewer job postings live on the website and far more competition for them.

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

--Longest losing streak since Aug. 5, 2022, when it fell for six straight trading days --Worst six day stretch since the six days ending March 25, 2020, when it fell 14.85% --Down 19.3% from its ...

AbCellera Forward-looking Statements. This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Secur ...

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help ...

Abcellera Biologics, Inc. ( (ABCL) ) has released its Q3 earnings. Here is a breakdown of the information Abcellera Biologics, Inc. presented ...

Despite a widened net loss, AbCellera Biologics Inc (ABCL) strengthens its pipeline and partnerships, maintaining robust ...